Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

PubWeight™: 5.80‹?› | Rank: Top 1%

🔗 View Article (PMID 7654275)

Published in JAMA on May 10, 1995

Authors

R Garg1, S Yusuf

Author Affiliations

1: Clinical Trials Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA.

Articles citing this

(truncated to the top 100)

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79

Performance indicators for primary care groups: an evidence based approach. BMJ (1998) 6.97

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ (1998) 6.41

Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart (1999) 4.04

Systematic review of multidisciplinary interventions in heart failure. Heart (2005) 3.68

Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46

Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ (1999) 3.16

North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ (1998) 2.72

Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health (1997) 2.51

Heart failure–associated hospitalizations in the United States. J Am Coll Cardiol (2013) 2.44

A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35

Taking precautions with ACE inhibitors. A theoretical risk exists in patients with unilateral renal artery stenosis. BMJ (1998) 2.32

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest (1996) 2.24

Increase in hospital admission rates for heart failure in The Netherlands, 1980-1993. Heart (1996) 2.10

Heart failure: Part I. First hospitalization and post-hospital care. West J Med (1999) 2.10

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ (2002) 1.99

Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A (2001) 1.97

The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ (2003) 1.94

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ (2004) 1.92

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest (1997) 1.88

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest (1997) 1.83

Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol (2004) 1.64

Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart (1998) 1.54

Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51

Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ (2008) 1.51

Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J (2013) 1.49

Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!). CMAJ (2001) 1.49

Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med (1997) 1.48

Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol (1997) 1.48

Ramipril use in Canada: HOPE or HYPE? CMAJ (2003) 1.45

Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ (2002) 1.45

Sex differences in risk factors, treatment and mortality after acute myocardial infarction: an observational study. J Epidemiol Community Health (2000) 1.43

The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol (2006) 1.43

Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ (1998) 1.32

Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ (2005) 1.23

Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med (2012) 1.22

Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ (2002) 1.22

Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes (2014) 1.19

Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol (2007) 1.15

Evidence into practice, experimentation and quasi experimentation: are the methods up to the task? J Epidemiol Community Health (1998) 1.13

Drug treatment in heart failure. BMJ (2000) 1.13

Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart (2002) 1.12

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart (1999) 1.08

Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation (2011) 1.01

Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br J Gen Pract (2000) 1.01

Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01

Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med (2009) 1.01

Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. J Card Fail (2006) 1.00

Combination therapy in hypertension: An update. Diabetol Metab Syndr (2010) 0.99

Fifth report on the provision of services for patients with heart disease. Heart (2002) 0.99

Medication adherence in heart failure. Heart Fail Rev (2007) 0.97

Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med (2010) 0.96

Gender and heart failure: a population perspective. Heart (2006) 0.96

Management of heart failure in the elderly. Heart Fail Rev (2002) 0.96

Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart (2004) 0.95

ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc (2009) 0.95

Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One (2013) 0.95

International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol Rev (2015) 0.94

A synopsis of research in cardiac apoptosis and its application to congestive heart failure. Tex Heart Inst J (2007) 0.94

Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev (2013) 0.93

Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme inhibitors. CMAJ (2000) 0.93

Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol (2014) 0.93

The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. BMC Cardiovasc Disord (2012) 0.93

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med (2013) 0.92

Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol (2004) 0.91

Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure. Hypertension (2012) 0.90

Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors. Int J Radiat Biol (2014) 0.90

Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol (2002) 0.90

The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90

Quality of care for heart failure among disabled Medicaid recipients with and without severe mental illness. Gen Hosp Psychiatry (2010) 0.89

The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure. Heart Fail Rev (2012) 0.89

Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J (2009) 0.89

Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial. BMC Geriatr (2012) 0.88

Aldosterone antagonists in systolic heart failure. Can Fam Physician (2014) 0.88

Cardiac 7-transmembrane-spanning domain receptor portfolios: diversify, diversify, diversify. J Clin Invest (2006) 0.88

Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract (2013) 0.88

Rationale and study design of a cross sectional study documenting the prevalence of Heart Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic--Echocardiographic Heart of England Screening Study). BMC Cardiovasc Disord (2009) 0.87

Heart failure among Indigenous Australians: a systematic review. BMC Cardiovasc Disord (2012) 0.87

Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol (2008) 0.86

Patients with worsening chronic heart failure who present to a hospital emergency department require hospital care. BMC Res Notes (2012) 0.86

Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study. Eur J Clin Pharmacol (2007) 0.85

Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. Curr Control Trials Cardiovasc Med (2005) 0.84

ELITE II and Val-HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med (2001) 0.83

Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol (2012) 0.83

Prevalence of left ventricular dysfunction in a UK community sample of very old people: the Newcastle 85+ study. Heart (2012) 0.83

Systolic heart failure in the elderly: optimizing medical management. Heart Fail Rev (2012) 0.82

Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction. Aging health (2008) 0.82

GENETIC CAUSES OF DILATED CARDIOMYOPATHY. Prog Pediatr Cardiol (2014) 0.82

Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J (2014) 0.82

Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. BMC Cardiovasc Disord (2006) 0.81

The effects of heart failure on renal function. Cardiol Clin (2010) 0.81

Sex-related differences in heart failure and beta-blockers. Heart Fail Rev (2004) 0.81

The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med (2001) 0.81

Heart failure in elderly: progress in clinical evaluation and therapeutic approach. J Geriatr Cardiol (2013) 0.80

Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol (2012) 0.80

Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart (2001) 0.80

Vascular-targeted therapies for Duchenne muscular dystrophy. Skelet Muscle (2013) 0.80

Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ (2008) 0.80

Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Curr Diab Rep (2016) 0.79

The use of angiotensin-converting enzyme inhibitors and other drugs with cardiovascular effects by non-demented and demented elderly with a clinical diagnosis of heart failure. A population-based study of the very old. Eur J Clin Pharmacol (2006) 0.79

Articles by these authors

(truncated to the top 100)

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20

Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (2006) 9.43

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38

Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01

Why do we need some large, simple randomized trials? Stat Med (1985) 7.67

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (2008) 7.05

An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83

Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 5.00

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45

Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28

Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96

Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79

Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72

Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63

Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60

Health and peace: time for a new discipline. Lancet (2001) 3.52

Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32

Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18

Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet (2001) 3.16

Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90

Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87

Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation (1999) 2.79

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61

ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol (1999) 2.35

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30

Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27

Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27

Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol (2000) 2.22

Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet (2000) 2.17

Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart (2009) 2.16

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 2.15

Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation (1993) 2.15

Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11

Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol (2001) 2.05

Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00

Can medicine prevent war? Imaginative thinking shows that it might. BMJ (1999) 1.95

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol (1991) 1.94

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials (1997) 1.88

Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88

Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation (1995) 1.85

Magnesium in acute myocardial infarction. BMJ (1995) 1.80

ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation (1999) 1.80

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76

Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) (2005) 1.72

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J (2000) 1.72

Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol (1996) 1.64

Increased risk of acute myocardial infarction associated with beedi and cigarette smoking in Indians: final report on tobacco risks from a case-control study. Indian Heart J (2002) 1.62

Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study. Heart (2009) 1.61

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA (1993) 1.60

Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol (1985) 1.60

Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol (1999) 1.59

Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol (2001) 1.58

Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA. Indian Heart J (1997) 1.58

Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol (1996) 1.55

Dual-chamber versus ventricular pacing. Critical appraisal of current data. Circulation (1996) 1.55

The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J (1984) 1.55

Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia (2010) 1.54

Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2002) 1.51

Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation (1998) 1.51

Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. JAMA (2001) 1.50

Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol (1993) 1.49

Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation (1995) 1.49

The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol (2003) 1.49

Validity of the US Behavioral Risk Factor Surveillance System's health related quality of life survey tool in a group of older Canadians. Chronic Dis Can (2001) 1.47

Urate levels as a predictor of cardiac deaths: causal relation or mere association? Eur Heart J (2002) 1.40

Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J (2002) 1.40

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care (2008) 1.37

Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials (1997) 1.36

Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). Indian Heart J (2001) 1.33

Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol (1997) 1.33

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail (1999) 1.32

Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA (1988) 1.29

Dysglycaemia and risk of cardiovascular disease. Lancet (1996) 1.29

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation (1996) 1.27

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J (2006) 1.24

The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22

Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J (2001) 1.22

Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. Am Heart J (1982) 1.21

A cardiologist's guide to waist management. Heart (2006) 1.20

Value of electrocardiogram in predicting and estimating infarct size in man. Br Heart J (1979) 1.18